Q3 Loss of $0.59 Per Share on $19.1M Sales
RMTI sits 45% above its 52-week low of $4.885.
Summary
Rockwell Medical posted a Q3 net loss of $2.324 million, or -$0.59 per share, on sales of $19.122 million. Sales grew from the $17.8 million reported in Q2, but the quarter still produced an operating loss of $2.221 million and gross profit of just $3.111 million. The loss lands as the company works through its pending acquisition of Vantive's global hemodialysis business for a $125M base price, funded entirely by debt, announced November 3rd. For a company of this size, a quarterly loss of this magnitude keeps the balance sheet and the financing of that deal front and center.
At the time of this announcement, RMTI was trading at $7.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.5M. The 52-week trading range was $4.89 to $12.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.